MDoutlook proudly presents the second study on the clinical impact of new data presented at ASCO 2015. This OncoPoll™ includes analyses from 2 studies in Gastrointestinal Cancers involving more than 160 oncologists.
Our MD/PhD research team reports the following analysis highlights:
Non-CRC GI Cancers
- Anti-PD-1 antibodies are expected to have a large impact for selected patients with Gastric, Esophageal and Hepatocellular Cancers
- At current drug costs, only average value is placed on these agents in GI cancers (lower than what is seen for NSCLC)
- 75% of the respondents expect the PEGH20 addition to have intermediate or high clinical impact on the treatment of pancreatic cancer
- Regorafenib will be widely used in advanced G/GEJ cancers upon regulatory approval
Metastatic Colorectal Cancer
- The immune checkpoint inhibitors (anti-PD-1/PD-L1) are going to have a very significant impact on the treatment landscape for MMR-deficient mCRC
– Over a quarter of mCRC patients with this deficiency are expected to receive this treatment almost immediately
– Most mCRC patients will now be tested for an MMR deficiency
- At today’s prices, physicians see good value in using the anti-PD-1/PD-L1 antibodies for mCRC
- Combining BRAF+/-MEK inhibitors with anti-EGFR antibodies is initially seen to have only a limited impact on the treatment of BRAF-mutated CRC
Download your complimentary copy of the MDoutlook 2015 ASCO Syndicated GI Cancers OncoPoll here.
MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide meaningful, timely and relevant insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.
MDoutlook is disease intelligence redefined. Governed by top ThoughtLeaders and driven by in-house MD and PhD medical experts, MDoutlook® is powered by a proprietary, global cloud-based disease intelligence platform accessing 1M+ multi-disciplinary treaters of complex diseases, including cancer, hematology, auto-immune diseases.
Email or phone (+1.404.496.4136 / 888.3outlook) to discuss how MDoutlook can answer your disease intelligence needs.